Pavel Raifeld
Vorstandsvorsitzender bei INNOVIVA, INC.
Vermögen: 184 206 $ am 31.05.2024
Aktive Positionen von Pavel Raifeld
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INNOVIVA, INC. | Vorstandsvorsitzender | 20.05.2020 | - |
ENTASIS THERAPEUTICS HOLDINGS INC. | Direktor/Vorstandsmitglied | 11.07.2022 | - |
LA JOLLA PHARMACEUTICAL COMPANY | Direktor/Vorstandsmitglied | 22.08.2022 | - |
Theravance Respiratory Co. LLC
Theravance Respiratory Co. LLC Pharmaceuticals: MajorHealth Technology Part of Royalty Pharma Plc, Theravance Respiratory Co. LLC is a company that manufactures inhaled corticosteroid products. The company is based in Burlingame, CA. The CEO of the company is Pavel Raifeld. Theravance Respiratory Co. was acquired by Royalty Pharma Plc from Theravance Biopharma, Inc. on July 20, 2022 for $1,350 million. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Pavel Raifeld
Ehemalige bekannte Positionen von Pavel Raifeld
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
Ausbildung von Pavel Raifeld
The Trustees of Columbia University in The City of New York | Masters Business Admin |
Harvard University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Operativ
Chief Executive Officer | 2 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INNOVIVA, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Regional BanksFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Finance |
Theravance Respiratory Co. LLC
Theravance Respiratory Co. LLC Pharmaceuticals: MajorHealth Technology Part of Royalty Pharma Plc, Theravance Respiratory Co. LLC is a company that manufactures inhaled corticosteroid products. The company is based in Burlingame, CA. The CEO of the company is Pavel Raifeld. Theravance Respiratory Co. was acquired by Royalty Pharma Plc from Theravance Biopharma, Inc. on July 20, 2022 for $1,350 million. | Health Technology |
Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Börse
- Insiders
- Pavel Raifeld
- Erfahrung